$APYX
Apyx Medical Corp Stock $apyx

$apyx Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000071913517000029 Filed on August 03, 2017

Income Statement

Concept	2017 Q2	2016 Q2
Revenue	$2.311M	$9.295M
YoY Change	-75.14%	27.78%
Cost Of Revenue	$4.757M	$4.595M
YoY Change	3.53%	11.26%
Gross Profit	$1.572M	$4.700M
YoY Change	-66.55%	49.68%
Gross Profit Margin	68.02%	50.56%
Selling, General & Admin	$2.929M	$2.022M
YoY Change	44.86%	-51.63%
% of Gross Profit	186.32%	43.02%
Research & Development	$696.0K	$592.0K
YoY Change	17.57%	16.08%
% of Gross Profit	44.27%	12.6%
Depreciation & Amortization	$178.0K	$173.0K
YoY Change	2.89%	-24.78%
% of Gross Profit	11.32%	3.68%
Operating Expenses	$6.348M	$5.210M
YoY Change	21.84%	11.09%
Operating Profit	-$1.306M	-$510.0K
YoY Change	156.08%	-67.1%
Interest Expense	$0.00	-$10.00K
YoY Change	-100.0%	-120.0%
% of Operating Profit
Other Income/Expense, Net	$2.000K	-$9.000K
YoY Change	-122.22%
Pretax Income	-$1.304M	-$519.0K
YoY Change	151.25%	-65.4%
Income Tax	$4.000K	$0.00
% Of Pretax Income
Net Earnings	-$1.308M	-$519.0K
YoY Change	152.02%	-65.4%
Net Earnings / Revenue	-56.6%	-5.58%
Basic Earnings Per Share	-$130.00	-$0.02
Diluted Earnings Per Share	-$0.04	-$0.02
COMMON SHARES
Basic Shares Outstanding	30.86M shares	27.05M shares
Diluted Shares Outstanding	30.86M shares	27.05M shares

Balance Sheet

Concept	2017 Q2	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.30M	$9.300M
YoY Change	10.75%	-34.04%
Cash & Equivalents	$10.29M	$9.324M
Short-Term Investments
Other Short-Term Assets	$1.300M	$1.300M
YoY Change	0.0%	-38.1%
Inventory	$7.582M	$6.400M
Prepaid Expenses
Receivables	$4.929M	$3.500M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$24.12M	$20.60M
YoY Change	17.09%	-15.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.240M	$6.500M
YoY Change	-4.0%	-7.14%
Goodwill	$185.0K
YoY Change
Intangibles	$1.510M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$218.0K	$500.0K
YoY Change	-56.4%	-28.57%
Total Long-Term Assets	$8.436M	$9.000M
YoY Change	-6.27%	-6.25%
TOTAL ASSETS
Total Short-Term Assets	$24.12M	$20.60M
Total Long-Term Assets	$8.436M	$9.000M
Total Assets	$32.56M	$29.60M
YoY Change	9.99%	-13.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.077M	$1.800M
YoY Change	15.39%	5.88%
Accrued Expenses	$2.511M	$2.600M
YoY Change	-3.42%	36.84%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$239.0K	$200.0K
YoY Change	19.5%	0.0%
Total Short-Term Liabilities	$5.618M	$4.600M
YoY Change	22.13%	17.95%
LONG-TERM LIABILITIES
Long-Term Debt	$2.575M	$3.000M
YoY Change	-14.17%	-3.23%
Other Long-Term Liabilities	$100.0K	$200.0K
YoY Change	-50.0%	-66.67%
Total Long-Term Liabilities	$2.575M	$3.200M
YoY Change	-19.53%	-13.51%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.618M	$4.600M
Total Long-Term Liabilities	$2.575M	$3.200M
Total Liabilities	$8.985M	$8.300M
YoY Change	8.25%	3.75%
SHAREHOLDERS EQUITY
Retained Earnings	-$26.43M
YoY Change
Common Stock	$31.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$23.57M	$21.30M
YoY Change
Total Liabilities & Shareholders Equity	$32.56M	$29.60M
YoY Change	9.99%	-13.2%

Cashflow Statement

Concept	2017 Q2	2016 Q2
OPERATING ACTIVITIES
Net Income	-$1.308M	-$519.0K
YoY Change	152.02%	-65.4%
Depreciation, Depletion And Amortization	$178.0K	$173.0K
YoY Change	2.89%	-24.78%
Cash From Operating Activities	-$1.070M	-$110.0K
YoY Change	872.73%	-95.28%
INVESTING ACTIVITIES
Capital Expenditures	-$80.00K	-$20.00K
YoY Change	300.0%	-90.48%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$80.00K	-$20.00K
YoY Change	300.0%	-90.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-60.00K	0.000
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities	-1.070M	-110.0K
Cash From Investing Activities	-80.00K	-20.00K
Cash From Financing Activities	-60.00K	0.000
Net Change In Cash	-1.210M	-130.0K
YoY Change	830.77%	-90.08%
FREE CASH FLOW
Cash From Operating Activities	-$1.070M	-$110.0K
Capital Expenditures	-$80.00K	-$20.00K
Free Cash Flow	-$990.0K	-$90.00K
YoY Change	1000.0%	-95.75%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q2	bvx	Dilutive Securities Effect On Basic Earnings Per Share Derivative Liability Warrant DilutiveSecuritiesEffectOnBasicEarningsPerShareDerivativeLiabilityWarrant	0	USD
	bvx	Dilutive Securities Effect On Basic Earnings Per Share Derivative Liability Warrant DilutiveSecuritiesEffectOnBasicEarningsPerShareDerivativeLiabilityWarrant	0	USD
CY2017Q2	bvx	Dilutive Securities Effect On Basic Earnings Per Share Derivative Liability Warrant DilutiveSecuritiesEffectOnBasicEarningsPerShareDerivativeLiabilityWarrant	0	USD
	bvx	Dilutive Securities Effect On Basic Earnings Per Share Derivative Liability Warrant DilutiveSecuritiesEffectOnBasicEarningsPerShareDerivativeLiabilityWarrant	0	USD
	bvx	Numberofproductlines Numberofproductlines	4	product_line
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000719135
	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30859753	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1606000	USD
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2077000	USD
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	BOVIE MEDICAL CORP
	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4733000	USD
CY2017Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4929000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2604000	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2511000	USD
CY2016Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	419000	USD
CY2017Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	416000	USD
CY2016Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	404000	USD
CY2017Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	375000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	49625000	USD
CY2017Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	49966000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	360000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	341000	USD
CY2016Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	184000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	360000	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	182000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	341000	USD
CY2016Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	27000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	54000	USD
CY2017Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	27000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	54000	USD
CY2016Q4	us-gaap	Assets Assets	35110000	USD
CY2017Q2	us-gaap	Assets Assets	32556000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	26539000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	24120000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11805000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9324000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14456000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10292000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2481000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4164000	USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31002832	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31002832	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30859753	shares
	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	126000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	792000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	14000	USD
CY2017Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	564000	USD
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30859753	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	31000	USD
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	31000	USD
CY2016Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4595000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9048000	USD
CY2017Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4757000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8920000	USD
CY2016Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	564000	USD
CY2017Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	11000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1507000	USD
CY2016Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	109000	USD
CY2017Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	66000	USD
CY2016Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	173000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	355000	USD
CY2017Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	178000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	356000	USD
CY2016Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	203000	USD
CY2017Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	77000	USD
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2016Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2017Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	215000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	217000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-14000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-2000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	185000	USD
CY2017Q2	us-gaap	Goodwill Goodwill	185000	USD
CY2016Q2	us-gaap	Gross Profit GrossProfit	4700000	USD
	us-gaap	Gross Profit GrossProfit	8022000	USD
CY2017Q2	us-gaap	Gross Profit GrossProfit	5042000	USD
	us-gaap	Gross Profit GrossProfit	9268000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-519000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2463000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1304000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2984000	USD
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	560000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	471000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	740000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	355000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-63000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-128000	USD
	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	44000	USD
	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	-72000	USD
	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	128000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	20000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	125000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-60000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2016Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Interest Paid InterestPaid	50000	USD
CY2017Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2016Q4	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	1510000	USD
CY2017Q2	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	1510000	USD
CY2016Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-50000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-88000	USD
CY2017Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-36000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-67000	USD
	us-gaap	Interest Paid InterestPaid	67000	USD
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3048000	USD
CY2017Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4189000	USD
CY2016Q4	us-gaap	Inventory Gross InventoryGross	7569000	USD
CY2017Q2	us-gaap	Inventory Gross InventoryGross	9076000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	6158000	USD
CY2017Q2	us-gaap	Inventory Net InventoryNet	7582000	USD
CY2016Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	4521000	USD
CY2017Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	4887000	USD
CY2016Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1411000	USD
CY2017Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1494000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	334000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	83000	USD
CY2016Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	37230	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	82280	USD
CY2017Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	43539	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	85326	USD
CY2016Q4	us-gaap	Liabilities Liabilities	8887000	USD
CY2017Q2	us-gaap	Liabilities Liabilities	8985000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35110000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	32556000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5272000	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5618000	USD
CY2017Q2	us-gaap	Long Term Debt LongTermDebt	2814000	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	239000	USD
CY2017Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	239000	USD
CY2017Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	120000	USD
CY2017Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	2455000	USD
CY2017Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	239000	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2694000	USD
CY2017Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2575000	USD
CY2016Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	140000	USD
CY2017Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	140000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-60000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-119000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-41000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-151000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2380000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3894000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-519000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2463000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	159000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-1308000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2993000	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-519000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2463000	USD
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1308000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2993000	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-519000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2463000	USD
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1308000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2993000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2016	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	5210000	USD
	us-gaap	Operating Expenses OperatingExpenses	10525000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	6348000	USD
	us-gaap	Operating Expenses OperatingExpenses	12311000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-510000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2503000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1306000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3043000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	498000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	87000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	59000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	59000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	118000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	175000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	103000	USD
CY2017Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	218000	USD
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-9000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	40000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	59000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	41000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	151000	USD
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	1000	USD
CY2017Q2	us-gaap	Preferred Stock Value PreferredStockValue	1000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	413000	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	538000	USD
	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	-120000	USD
	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	-119000	USD
CY2016Q2	us-gaap	Professional Fees ProfessionalFees	396000	USD
	us-gaap	Professional Fees ProfessionalFees	753000	USD
CY2017Q2	us-gaap	Professional Fees ProfessionalFees	480000	USD
	us-gaap	Professional Fees ProfessionalFees	870000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6449000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6240000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	159000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	696000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1405000	USD
CY2017Q2	us-gaap	Purchase Obligation PurchaseObligation	4000000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	592000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1259000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	779000	USD
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	779000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23434000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-26427000	USD
CY2016Q2	us-gaap	Salaries And Wages SalariesAndWages	2200000	USD
	us-gaap	Salaries And Wages SalariesAndWages	4300000	USD
CY2017Q2	us-gaap	Salaries And Wages SalariesAndWages	2243000	USD
	us-gaap	Salaries And Wages SalariesAndWages	4703000	USD
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	9295000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	17070000	USD
CY2017Q2	us-gaap	Sales Revenue Net SalesRevenueNet	9799000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	18188000	USD
CY2016Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2022000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4213000	USD
CY2017Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2929000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5333000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	360000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	341000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.680
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.015
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	203803	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	4.84
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	505000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3752209	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4053406	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.04
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.98
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.32
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	23404000	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	21301000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	26223000	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	23571000	USD
CY2016Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	41000	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	128000	USD
CY2017Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	38000	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	126000	USD
CY2016Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	27051000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	27051000	shares
CY2017Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	30860000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	30860000	shares
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27051000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27051000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30860000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30860000	shares
CY2016Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	27051000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	27051000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	30860000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	30860000	shares
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27051000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27051000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30860000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30860000	shares
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RECENT ACCOUNTING PRONOUNCEMENTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other</font><font style="font-family:inherit;font-size:10pt;"> (Topic 350): </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Simplifying the Test for Goodwill Impairment</font><font style="font-family:inherit;font-size:10pt;">. The purpose of this ASU is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this ASU, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit's fair value. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted, however we have chosen not to do so. The amendment is not expected to have a material impact on our financial condition or results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU 2016-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:inherit;font-size:10pt;">. The new guidance clarifies the classification of certain cash receipts and cash payments in the statement of cash flows, including debt prepayment or extinguishment costs, settlement of contingent consideration arising from a business combination, insurance settlement proceeds, and distributions from certain equity method investees. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early adoption is permitted, however we have chosen not to do so. The amendment is not expected to have a material impact on our financial condition or results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, FASB issued ASU No. 2016-09</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Compensation-Stock Compensation - (Topic 718)</font><font style="font-family:inherit;font-size:10pt;"> Improvements to employee share-based payments accounting as part of simplicity initiatives. This update involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Some of the areas for simplification apply only to nonpublic entities. For us, the amendments in this Update are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The amendment has not made a material impact on our financial condition or results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, FASB issued ASU No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU No. 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for us on January 1, 2018. Early adoption is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The amendment is not expected to have a material impact on our financial condition or results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</font></div></div>

Files In Submission

Name	View Source	Status
0000719135-17-000029-index-headers.html	Edgar Link	pending
0000719135-17-000029-index.html	Edgar Link	pending
0000719135-17-000029.txt	Edgar Link	pending
0000719135-17-000029-xbrl.zip	Edgar Link	pending
a2017q210-q.htm	Edgar Link	pending
a2017q210-qexhibit311.htm	Edgar Link	pending
a2017q210-qexhibit312.htm	Edgar Link	pending
a2017q210-qexhibit321.htm	Edgar Link	pending
a2017q210-qexhibit322.htm	Edgar Link	pending
bovielogo2017.jpg	Edgar Link	pending
bvx-20170630.xml	Edgar Link	completed
bvx-20170630.xsd	Edgar Link	pending
bvx-20170630_cal.xml	Edgar Link	unprocessable
bvx-20170630_def.xml	Edgar Link	unprocessable
bvx-20170630_lab.xml	Edgar Link	unprocessable
bvx-20170630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APYX
Apyx Medical Corp Stock $apyx

2017 Q2 Form 10-Q Financial Statement

#000071913517000029 Filed on August 03, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYX Apyx Medical Corp Stock $apyx

2017 Q2 Form 10-Q Financial Statement

#000071913517000029 Filed on August 03, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYX
Apyx Medical Corp Stock $apyx